Key Stats for GE HealthCare Stock
- This Week Performance: 3%
- 52-Week Range: $58 to $92
- Current Price: $83
What Happened to GE Healthcare Stock?
GE HealthCare (GEHC) shares held strong and gained 3% this week, trading quietly after a busy stretch of product and contract news that reinforced the company’s position as one of the most active innovators in medical imaging and diagnostics.
Just yesterday, the FDA granted 510(k) clearance for three next-generation MRI systems: SIGNA Sprint with Freelium, SIGNA Bolt, and the AI-driven SIGNA One workflow ecosystem, capping a product launch cycle CEO Peter Arduini called the biggest in a decade.
The clearances built on momentum from the February 4 earnings call, where GE HealthCare reported Q4 organic revenue growth of 4.8%, record backlog of $21.8 billion, and full year free cash flow of $1.5 billion, all exceeding expectations despite absorbing $245 million in tariff headwinds.
The market is beginning to see GE HealthCare less as a legacy imaging hardware company and more as a diversified diagnostics and AI platform, with Flyrcado ramping, Intelerad closing in H1 2026, and a $35 million BARDA expansion funding AI-powered ultrasound for trauma care announced February 17.
The nine major product launches entering the order book throughout 2026 and converting to revenue in 2027 represent the clearest path to management’s medium-term targets of mid-single-digit revenue growth and high-teens to 20% plus adjusted EBITDA margins.
Where is the GEHC Stock Headed?
With triple FDA clearances, a BARDA expansion, and the Intelerad acquisition closing in H1 2026, GE HealthCare enters the back half of the year with more identifiable growth catalysts than at any point since its 2023 spinoff from GE.
The fundamental case rests on Street estimates projecting 2026 revenue of $21.6 billion (+4.9% YoY) and normalized EPS of $5.06 (+10.1%), with EBITDA margins expanding to 18.5% as nine major product launches begin converting backlog into revenue.
14 analysts rate the GE Healthcare stock a Buy or Outperform against just 6 Holds and 1 Sell, with a mean price target of $93.25 as of February 20, implying roughly 12.3% upside from the current price of $83.01.
The target range spans from a low of $75 to a high of $110, a spread that reflects genuine uncertainty around China’s recovery timeline, Flyrcado’s ramp pace, and how quickly the nine RSNA product launches translate into orders and revenue.
A mid-case DCF model prices GE HealthCare at $113.14 by December 2030, implying a 36.3% total return and a 6.6% annualized IRR from current levels, a modest but steady return profile that reflects the company’s still-maturing innovation cycle.
The primary risk is that the GEHC stock sits just below its 52-week high of $92.20 while trading at a P/E that the model expects to compress 0.8% annually, meaning GE HealthCare must sustain nearly 7% EPS growth just to hold its current valuation multiple.
At $83.01, GE Healthcare stock looks modestly undervalued relative to analyst consensus but represents more of a patient, multi-year compounder than a near-term momentum trade, with the real earnings inflection story arriving in 2027 when the new product cycle hits full stride.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
